Study: NCT03636906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) higher dose formulation vaccine
Description: 2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's multicomponent meningococcal B vaccine
Description: 3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's multicomponent meningococcal B vaccine
Description: 3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's multicomponent meningococcal B vaccine
Description: 3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's pneumococcal polysaccharide conjugate vaccine
Description: 3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's pneumococcal polysaccharide conjugate vaccine
Description: 3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's pneumococcal polysaccharide conjugate vaccine
Description: 3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.